|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Masoud_Toloue
|
|
gptkbp:focusesOn
|
oncology research
infectious disease research
digital immunoassay
neurology research
protein biomarker analysis
|
|
gptkbp:foundedYear
|
2007
|
|
gptkbp:founder
|
gptkb:David_Walt
|
|
gptkbp:headquartersLocation
|
gptkb:Billerica,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Quanterix Corporation
|
|
gptkbp:industry
|
gptkb:biotechnology
life sciences
|
|
gptkbp:market
|
global
|
|
gptkbp:notableCollaboration
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Alzheimer's_Disease_Neuroimaging_Initiative
gptkb:NHLBI_(National_Heart,_Lung,_and_Blood_Institute)
|
|
gptkbp:notableProduct
|
gptkb:Simoa_HD-X_Analyzer
gptkb:Simoa_SP-X_Imaging_and_Analysis_System
gptkb:Simoa_SR-X_Analyzer
|
|
gptkbp:numberOfEmployees
|
approximately 400 (2023)
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:servesIndustry
|
pharmaceutical research
clinical diagnostics
|
|
gptkbp:specializesIn
|
ultrasensitive biomarker detection
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:QTRX
|
|
gptkbp:technology
|
gptkb:Simoa_(Single_Molecule_Array)
|
|
gptkbp:website
|
https://www.quanterix.com/
|
|
gptkbp:bfsParent
|
gptkb:Simoa
|
|
gptkbp:bfsLayer
|
7
|